큐 바이오파마, Inc.

SecurityCUE / Cue Biopharma, Inc.
InstitutionVanguard Group Inc
Latest Disclosed Ownership3,014,034 shares
Latest Disclosed Value $ 919,280
Vanguard Group Inc reports 0.83% decrease in ownership of CUE / Cue Biopharma, Inc.

On January 29, 2026 - Vanguard Group Inc filed a 13F-HR form disclosing ownership of 3,014,034 shares of Cue Biopharma, Inc. (US:CUE) valued at $920,486 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 7, 2025 disclosing 3,039,322 shares of Cue Biopharma, Inc.. This represents a change in shares of -0.83% during the quarter. The current value of the position is $88,793,442 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-01-29 2025-12-31 13F CUE BIOPHARMA COM 22978P106 3,014,034 -25,288 -0.83 919 -57.94 0.0000
2025-11-07 2025-09-30 13F CUE BIOPHARMA COM 22978P106 3,039,322 -148,024 -4.64 2,185 0.55 0.0000
2025-08-11 2025-06-30 13F CUE BIOPHARMA COM 22978P106 3,187,346 871,484 37.63 2,174 3.03 0.0000
2025-05-09 2025-03-31 13F CUE BIOPHARMA COM 22978P106 2,315,862 259,686 12.63 2,110 -5.89 0.0000
2025-02-11 2024-12-31 13F CUE BIOPHARMA COM 22978P106 2,056,176 24,755 1.22 2,241 45.80 0.0000
2024-11-13 2024-09-30 13F CUE BIOPHARMA COM 22978P106 2,031,421 0 0.00 1,538 -38.96 0.0000
2024-08-13 2024-06-30 13F CUE BIOPHARMA COM 22978P106 2,031,421 -251,941 -11.03 2,519 -41.65 0.0000
2024-05-10 2024-03-31 13F CUE BIOPHARMA COM 22978P106 2,283,362 150,457 7.05 4,316 -23.36 0.0001
2024-03-11 2023-12-31 13F/A-1 CUE BIOPHARMA COM 22978P106 2,132,905 7,999 0.38 5,631 15.20 0.0001
2024-02-14 2023-12-31 13F CUE BIOPHARMA COM 22978P106 2,132,905 7,999 5,631 0.0001
2023-12-18 2023-09-30 13F/A-1 CUE BIOPHARMA COM 22978P106 2,124,906 76,382 3.73 4,887 -34.64 0.0001
2023-11-14 2023-09-30 13F CUE BIOPHARMA COM 22978P106 2,124,906 76,382 4,887 0.0000
2023-08-14 2023-06-30 13F CUE BIOPHARMA COM 22978P106 2,048,524 394,928 23.88 7,477 26.66 0.0002
2023-07-14 2023-03-31 13F/A-1 CUE BIOPHARMA COM 22978P106 1,653,596 124,666 8.15 5,903 35.48 0.0002
2023-05-15 2023-03-31 13F CUE BIOPHARMA COM 22978P106 1,653,596 124,666 5,903 0.0002
2023-02-10 2022-12-31 13F CUE BIOPHARMA COM 22978P106 1,528,930 6,611 0.43 4,357 28.34 0.0001
2022-11-14 2022-09-30 13F CUE BIOPHARMA COM 22978P106 1,522,319 0 0.00 3,395 -10.45 0.0001
2022-08-12 2022-06-30 13F CUE BIOPHARMA COM 22978P106 1,522,319 -131,418 -7.95 3,791 -53.02 0.0001
2022-05-13 2022-03-31 13F CUE BIOPHARMA COM 22978P106 1,653,737 102,423 6.60 8,070 -54.01 0.0002
2022-02-14 2021-12-31 13F CUE BIOPHARMA COM 22978P106 1,551,314 -22,406 -1.42 17,546 -23.48 0.0004
2021-11-12 2021-09-30 13F CUE BIOPHARMA COM 22978P106 1,573,720 16,002 1.03 22,930 26.36 0.0006
2021-08-13 2021-06-30 13F CUE BIOPHARMA COM 22978P106 1,557,718 3,268 0.21 18,147 -4.31 0.0005
2021-05-14 2021-03-31 13F CUE BIOPHARMA COM 22978P106 1,554,450 109,913 7.61 18,965 4.95 0.0005
2021-02-12 2020-12-31 13F CUE BIOPHARMA COM 22978P106 1,444,537 63,621 4.61 18,070 -13.05 0.0005
2020-11-16 2020-09-30 13F CUE BIOPHARMA COM 22978P106 1,380,916 43,256 3.23 20,782 -36.61 0.0007
2020-08-14 2020-06-30 13F CUE BIOPHARMA COM 22978P106 1,337,660 410,373 44.26 32,785 149.15 0.0012
2020-05-15 2020-03-31 13F CUE BIOPHARMA COM 22978P106 927,287 37,571 4.22 13,159 -6.84 0.0006
2020-02-14 2019-12-31 13F CUE BIOPHARMA COM 22978P106 889,716 134,564 17.82 14,125 121.88 0.0005
2019-11-14 2019-09-30 13F CUE BIOPHARMA COM 22978P106 755,152 143,001 23.36 6,366 15.66 0.0002
2019-08-14 2019-06-30 13F CUE BIOPHARMA COM 22978P106 612,151 154,639 33.80 5,504 55.66 0.0002
2019-05-15 2019-03-31 13F CUE BIOPHARMA COM 22978P106 457,512 163,240 55.47 3,536 155.68 0.0001
2019-02-14 2018-12-31 13F CUE BIOPHARMA COM 22978P106 294,272 -367,344 -55.52 1,383 -76.90 0.0001
2018-12-13 2018-09-30 13F/A-2 CUE BIOPHARMA COM 22978P106 661,616 -6,723 -1.01 5,987 -24.46 0.0002
2018-11-23 2018-09-30 13F/A-1 CUE BIOPHARMA COM 22978P106 661,616 0 5,987 0.0002
2018-11-14 2018-09-30 13F CUE BIOPHARMA COM 22978P106 661,616 -6,723 5,987
2018-08-14 2018-06-30 13F CUE BIOPHARMA COM 22978P106 668,339 216,476 47.91 7,926 24.84 0.0003
2018-05-15 2018-03-31 13F CUE BIOPHARMA COM 22978P106 451,863 451,863 6,349 0.0003
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.